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Available online 2 April 2013Abstract Understanding how to specify rapid differentiation of human neural progenitor towards enriched non-transformed
human astrocyte progenitors will provide a critical cell source to further our understanding of how astrocytes play a pivotal role
in neural function and development. Human neural progenitors derived from pluripotent embryonic stem cells and propagated
in adherent serum-free cultures provide a fate restricted renewable source for quick production of neural cells; however, such
cells are highly refractive to astrocytogenesis and show a strong neurogenic bias, similar to neural progenitors from the early
embryonic central nervous system (CNS). We found that several astrocytic genes are hypermethylated in such progenitors
potentially preventing generation of astrocytes and leading to the proneuronal fate of these progenitors. However,
epigenetic modification by Azacytidine (Aza-C) and Trichostatin A (TSA), with concomitant signaling from BMP2 and LIF in
neural progenitor cultures shifts this bias, leading to expression of astrocytic markers as early as 5 days of differentiation,
with near complete suppression of neuronal differentiation. The resultant cells express major astrocytic markers, are
amenable to co-culture with neurons, can be propagated as astrocyte progenitors and are cryopreservable. Although previous
reports have generated astrocytes from pluripotent cells, the differentiation required extensive culture or selection based on
cell surface antigens. The development of a label free and rapid differentiation process will expedite future derivation of
astrocytes from various sources pluripotent cells including, but not limited to, human astrocytes associated with various
neurological diseases.
© 2013 Elsevier B.V. All rights reserved.Introduction nervous system. Understanding the biology of human astro-Astrocytes are crucial to multiple aspects of nerve function
and surpass neurons in abundance in the human central⁎ Corresponding author. Fax: +1 706 583 0071.
E-mail address: sstice@uga.edu (S.L. Stice).
1873-5061/$ - see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.scr.2013.03.003cytes or their potential in therapy is, however, undermined by
lack of a steady source of non-transformed human astrocytes.
Most researchers depend on primary astrocytes from mouse,
or on human astrocytes from limited sources such as fetal
brains or gliomas. Both are of limited availability, are mixed
populations and likely subject to variability due to source.
Additionally, astrocytes from glioma origin have abnormalities
575Astrocyte differentiation from human embryonic stem cellsrelated to cancer (Gonzalez-Gomez et al., 2003; Yan et al.,
2009).
Although Human Embryonic (hES) and induced Pluripotent
Stem (hiPS) cells are potential sources of unlimited quantities
of astrocytes, suitable methods for quick and controlled
differentiation of astrocytes from these cells are not avail-
able. When ES cells are differentiated as embryoid bodies (EB)
in suspension culture, both neurons and astrocytes are
produced within a largely uncontrolled mix of mature
phenotypes. Also generation of a clean populationmay require
months of culture, delaying and potentially hampering the
utility of hES or hiPS as sources of astrocytes for applications
where multiple new pluripotent cell lines from additional
genotypes must be quickly differentiated to astrocytes
(Krencik et al., 2011). The EB cultures display mixed
phenotypes and the means of directing differentiation are by
nature inefficient because the various differentiating cells are
not uniformly exposed to chemical/growth factor cocktails.
Enriching astrocytes from such cultures requires flow cytom-
etric cell sorting (FACS) or microbead-based separation based
upon phenotypic markers (Yuan et al., 2011). However, this
method is limited since the cultures must be either mechan-
ically or enzymatically dissociated into single cells, which
induces contractility-mediated programmed cell death (Chen
et al., 2010; Ohgushi et al., 2010). The ability to quickly and
separately derive both neurons and astrocytes that share the
same cell source and hence the same genetic background,
combined with iPS technology, will open up the possibility of
designing patient- or population-specific tissue, representa-
tive screening and therapeutic approaches.
Other than the spontaneous production of astrocytes from
hES cells, specification of astrocytes in more directed
differentiation approaches has been described (Krencik et
al., 2011; Gupta et al., 2012). Although highly enriched
astrocyte cultures are produced, the process takes as long as
3 months and involves culture as 3 dimensional aggregates of
cells (Krencik et al., 2011). An alternative approach for quick
derivation of astrocytes utilizes an intermediate fate restrict-
ed population: human neural progenitors (hNP) derived from
ES/iPS cells. Adherent hNP cells differentiate readily to form
neurons that express numerous mature neuronal markers
(Young et al., 2011). However, astrocytogenesis from hNP
cells, although faster thanwhen startingwith hES, is still a long
term differentiation process (greater than 125 days) and
produces mixed populations rich in neurons (Young et al.,
2011). Despite the length of time required to derive astrocytes
from hNP cells there are several advantages to this process.
First it eliminates the time and variability associated with ES/
iPS cell culture and differentiation. Human NP cells derived
from pluripotent cells are self-renewing, and can be expanded
as required prior to further differentiation (Shin et al., 2006;
Dhara et al., 2008), thus offering a renewable source of human
astrocytes. Moreover differentiation in adherent monolayer
cultures offers uniform access, increasing the ability to
manipulate cells by chemical supplementation or manipula-
tion by transfection, transduction, and RNAi approaches. To
exploit these hNP cells as a consistent source of astrocytes,
one has to be able to switch their proneuronal bias to a
proastrocytic one.
Understanding of potential mechanisms involved in the
initial inherent neuronal bias of cultures and then using small
molecules to alter this bias towards astrocyte lineages willenable uniform and faster processes to generate astrocytes.
Here we explore the epigenetic mechanism that maintains the
proneuronal character of hNP cells and prevents generation of
astrocytes. We also describe amethod utilizing small molecules
in a chemically defined, serum-free media to shift the bias of
hNP cells from a proneuronal to a proastrocytic state, leading
ultimately to the production of highly enriched astrocytic
cultureswithin a very short time. These cells express prominent
astrocytic markers in as little as 5 days of differentiation and
generate highly enriched populations of astrocytes, making it
possible to generate either neurons or astrocytes from the same
progenitor source. Additionally, derivation and subsequent
maintenance in the same basal media as neurons make these
cells amenable to co-culture. The method also produces near
complete suppression of neuronal fates, thus further improving
the utility of the derived astrocytes.
Materials and methods
Cell culture and differentiation
Human neural progenitor (hNP) cell derivation from hES cells
has been described previously (Dhara et al., 2008). hNP cells
were propagated as adherent monolayer cultures in prolifer-
ation media (Neurobasal™, 1× B27, 1× Glutamax™, P/S, FGF2
10 ng/mL) as described (Shin et al., 2006). For neuronal
differentiation FGF2 was removed from the propagation media
(termed neuronal differentiation media). For astrocytic differ-
entiation of hNP cells, neuronal differentiation media were
supplemented with BMP2 (20 ng/mL) and combinations
of Aza-C and TSA; Aza-C (500 nM), TSA (100 nM) and BMP2
(20 ng/mL) for 2 days, with one complete media change in
between, followed by differentiationmedia supplementedwith
BMP2 but not with Aza-C or TSA. Cells were harvested prior to
analysis at 5, 15 or 30 days of treatment or for cryopreservation
at d6 or d10 of differentiation. For cryopreservation, cells were
dissociated with Accutase™ and frozen in differentiation
media containing10% DMSO. Viability was assessed at 30 days
in Aza-C and TSA treated cultures by trypan blue exclusion,
and datawas acquired using a Cellometer Auto T4® (Nexcelom
Biosciences).
Immunocytochemistry, flow-cytometry and real time
quantitative polymerase chain reaction
Immunocytochemistry and flow cytometry were performed
as previously described (Majumder et al., 2012). hNP cells
were differentiated in adherent culture as above and
dissociated with Accutase™. For staining adherent cultures,
cells were re-plated on Matrigel coated chamber slides
2 days prior to fixation in 4% PFA at d15 and d30. Antibodies
used for immunocytochemistry of adherent cultures were
S100B (1:200, DAKO), GFAP (1:500, Abcam), GLAST (1:200,
Abcam), and ALDH1L1 (1:200, Abcam). For flow-cytometry
dissociated cells were stained with S100B (1:200, DAKO),
GFAP (1:100, Abcam) and GLAST (1:200, Abcam). Alexafluor
(Invitrogen) dye conjugated secondary antibodies were used
at 1:1000 for slides and 1:5000 for flow cytometry.
Total RNA was isolated using RNeasy Plus kit (Qiagen) and
reverse transcribed using iScript cDNA kit. Real time qPCR was
performed on an ABI Prism7900HT. Inventoried Taqman™
576 A. Majumder et al.assays were used for all genes assayed. 3 replicates were run
unless otherwise mentioned. Data was analyzed using SDS2.4
and DataAssist3.01 software (Applied Biosystems).
Bisulfite sequencing analysis
Wecomparedmethylation in hNP cells with that in populations
differentiated in neuronal differentiation media (UT), differ-
entiation media with BMP2 (BMP2), with BMP2, Aza-C 500 nM,
TSA 10 nM (BMP2, Aza-C, TSA 10) or with BMP2, Aza-C 500 nM
and TSA 20 nM (BMP2, Aza-C, TSA 20).
Genomic DNA was extracted, treated with the Bisulfite
Conversion Kit (CpG Genome) and used for PCR as previously
described (Zhang et al., 2012). The primer sequences are
specific for the converted DNA sequence of the analyzed
regions and are available upon request. PCR products were
subsequently cloned using the TOPOTA cloning kit (Invitrogen),
and colonies were picked and plasmid DNA from each clonewas
prepared. DNA was sequenced and analyzed with BiQ analyzer
(Bock et al., 2005).
Quantitative chromatin immunoprecipitation (qChIP)
ChIP assays were performed as described previously (Zhang
et al., 2012). Briefly, chromatin was crosslinked with
formaldehyde and sheared by sonication. 20 μL of
Dynabeads Protein G (Invitrogen) was incubated with 2 μg
of antibody for 7 h at 4 °C, washed prior to incubation with
40 μg of soluble chromatin overnight at 4 °C. Dynabeads
were subsequently washed and protein/DNA complexes were
eluted in Elution Buffer (50 mM Tris–Cl pH 8.0, 10 mM EDTA
pH 8.0, 1% SDS) by incubation at 65 °C for 15 min. Protein/
DNA complex was reverse cross-linked by incubation over-
night at 65 °C. DNA was purified with a Qiagen DNA Isolation
column (Qiagen), and quantified by real-time PCR for
specific DNA fragments using the iQ SYBR Green Supermix
(BioRad) and a MyIQ Real-Time PCR Detection System
(BioRad). The values from ChIP with control antibody (IgG)
were typically less than 5% of the ChIP values with the
antibodies against histone modifications. The following
antibodies were used: anti-H3K4me3 (Millipore 07-473),
anti-H3K9Ac (Millipore 07-352); anti-H3 (Abcam 1791) and
IgG (Millipore 12-370).
Statistical analysis
Student's t-test was used to compare data for this study at
p b 0.05 level of significance. Analysis of variance (ANOVA)
followed by Tukey's test was conducted either by using SAS
8.01 (SAS Institute, Cary, NC) or Daniel's XL toolbox (a free,
open source add-in for Microsoft Excel) for all multiple
comparison data.
Results
Differentiating hNP cells do not express astrocytic
markers
Human NP cells (hNP) are derived from human embryonic
stem cells and cultured in the presence of FGF2 (Dhara etal., 2008). Upon withdrawal of FGF2 from hNP cells, cultures
begin to differentiate towards neurons (Young et al., 2011).
Since BMP2 and LIF are known pro-astrocytic growth factors
(Nakashima et al., 1999), we determined whether hNP cells
could form astrocytes when subjected to BMP2 and LIF after
FGF2 withdrawal, using qPCR analysis for the proneuronal
gene NEUROD1, the astrocyte progenitor gene CD44, and
astrocytic markers S100B and GFAP.
Compared to undifferentiated hNP cells, cultures differen-
tiated without BMP2 had significant (p b 0.05) up-regulation
of NEUROD1 (over 100 fold), which was markedly curbed with
BMP2 treatment (Fig. 1A). Expression of CD44 and S100B was
reduced in differentiated cells (p b 0.05) compared to hNP
cells at all three time points, irrespective of presence or
absence of BMP2 treatment (Fig. 1B), although down regula-
tion was more pronounced in BMP− cultures (Fig. 1C).
In long term BMP+ cultures (60 days) we detected a few
S100B+ and GFAP+ cells (Fig. 1D). These were mixed cultures,
proneuronal and visually the proportion of astrocytes and
neurons varied greatly between cultures. GFAP transcript
could also be detected at this time point (~2 months of
differentiation) in the BMP2+ cultures.
Pro-astrocytic gene promoters are hypermethylated
in hNP cells cultured in FGF2-containing medium
Since hypermethylation at promoter regions of astrocytic
genes have previously been reported for neural progenitors
isolated from the early mouse embryo (Fan et al., 2005;
Takizawa et al., 2001), we characterized hNP cells for DNA
methylation status of several relevant astrocytic and neuronal
genes using an Illumina methylation array. Promoters of 3
prominent astrocytic genes, GFAP, S100B and AQP4, were
hypermethylated in hNP cells (Fig. 1E), while the promoters
for proneuronal genes NEUROD1, NEUROG1, NEUROG2 and
NEUROG3 were hypomethylated. However, promoter of
proneuronal gene NEUROD6 was found to be hypermethylated
(Fig. 1F), consistent with previous reports that not all neural
progenitors express NEUROD6. For example this gene by itself
is dispensable for cortical development (Wu et al., 2005).
Several other astrocytic gene transcripts that are usually
expressed in astrocytes (Fatemi et al., 2008; Cahoy et al.,
2008) were found hypomethylated (GDNF, BDNF, VIM,
ALDH1L1 and CLU) (Fig. 1E). Hypermethylation of CD44,
S100B, GFAP and AQO4 promoters was further confirmed by
bisulfate sequencing (Fig. 5).
Concomitant treatment with Aza-Cytidine,
Trichostatin-A and BMP2 promotes early differ-
entiation of hNP cells to astrocytic fates
To modulate the epigenetic status of hNP cells, we treated
them with DNA methyltransferase inhibitor Aza-Cytidine
(Aza-C), and histone deacetylase inhibitor Trichostatin-A
(TSA). Combinations of Aza-C, TSA and BMP2 (listed in
Fig. 2A) were analyzed for effects on expression of the
astrocyte progenitor marker CD44 and the astrocyte marker
S100B. After 5 days of differentiation, cultures treated with
BMP2 alone and Aza-C alone showed no significant up-
regulation of either CD44 or S100B gene expression (Figs. 2A
and B). In contrast, there was a ~50 fold up-regulation of
Figure 1 Effect of BMP2 on differentiation of human neural progenitors (hNP). Quantitative PCR detection of (A) neuronal marker
NEUROD1, (B) astrocytic progenitor marker CD44 and (C) astrocytic marker S100B in differentiating hNP cells with or without a 5 day
BMP2 treatment starting 5, 10 and 15 days post withdrawal of FGF2. Expression levels are calibrated to starting hNP population.
Shown are the means ± SE for replicates (n = 3). Gray and black bars represent treatments without and with BMP2, respectively. (*)
on bars indicates level of significance at p b 0.05. (D) Few S100B and GFAP immunoreactive cells are detected in culture
differentiated for 60 days, including a 30 day BMP2 treatment. (E) Using an Illumina Methylation array, major pro-astrocytic gene
promoters (GFAP, AQP4, and S100B) were found be hypermethylated (~80%), whereas (F), pro-neuronal genes (NEUROD1, NEUROD2,
NEUROD4, NEUROG1, NEUROG2 and NEUROG3) were found to be hypo-methylated in hNP cells. Multiple loci for each gene were
tested where probes were available and each bar represents one probe.
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transcripts in cultures supplemented with BMP2 and Aza-C
combined, compared to the starting hNP population.
Treatment with Aza-C and TSA together, but with no
concomitant BMP2 during the first 2 days, also led to N30
fold increase in CD44 expression and N150 fold increase in
S100B gene expression (p b 0.05). However this treatment
also produced the highest observed cell death amongst all
the treatments. Concomitant treatment with BMP2 during
the initial 2 day treatment with Aza-C and TSA maximizedexpression (p b 0.05) of both CD44 (Fig. 2A) and S100B
(Fig. 2B).
All Aza-C and TSA concentrations used above resulted in
significant cell death; thus, we tested lower dose range
responses for both compounds. No CD44 expression was
detected in cells differentiated in neuronal differentiation
media (referred to as untreated (UT) from here onwards)
(Fig. 2C). With BMP2 alone (Aza-C 0 nM) expression level of
CD44 was less than the starting hNP population. However, a
dose dependent significant increase in CD44 expression was
578 A. Majumder et al.observed between Aza-C 100 nM and 500 nM reaching N6
fold over hNP with Aza-C 500 nM (p b 0.05) (Fig. 2C). No
further increase was seen with Aza-C at 1000 nM. A similar
Aza-C dose dependency was evident for S100B, with no gene
expression observed in UT control, and a 0, ~5 and ~10 fold
increase over hNP at Aza-C concentrations of 0, 100 and
500 nM. At 1000 nM of Aza-C, expression of S100B was
reduced (however, it was still 8 fold over hNP) (p b 0.05)
(Fig. 2D). In the same experimental setup, a TSA dose
dependent increase in expression of S100B but not CD44
transcripts was observed (p b 0.05) (Figs. 2F and E).
We further assessed expression of the astrocytic markers
ALDH1L1, and GDNF, as well as the neuronal differentiation
marker NeuroD1. ALDH1L1 transcripts were detected with
all Aza-C containing conditions, with an increase at 500 μM
over 100 μM. The highest response was noted at treatment
with 500 nM Aza-C and 10 μM TSA (p b 0.05). No increase
was seen in conditions containing TSA alone and no
transcripts were detected in the untreated (UT) populations
(Fig. 2G). GDNF expression was detected in all conditions
containing Aza-C and no dose dependent effect of TSA was
obvious. Similar to ALDH1L1, presence of 500 nM Aza-C and
10 nM TSA led to the highest expression levels of GDNF
(p b 0.05) (Fig. 2H). Additionally, we tested expression of
the astrocytic marker GFAP, but no GFAP transcripts were
detected in the 5 day differentiated hNP cells irrespective of
treatment (data not shown). NEUROD1 transcripts were
detected in the starting hNP population. After differentia-
tion, the untreated population had 60 fold higher expression
of NEUROD1, while no transcripts were detected in any of
the treated populations tested (Fig. 2I). Based on these
data, the Aza-C 500 nM, TSA 10 or 20 nM and BMP2 20 ng/mL
treatment was optimal for astrocytic differentiation of hNP
cells and used in subsequent studies.Morphological changes and expression of astrocyte
markers after further differentiation
Human NP cells were treated with differentiation media
containing Aza-C, TSA and BMP2 for two days and then
maintained in differentiation media with BMP2 for a total of
15 days. Compared to untreated cultures, almost all cells in
the treated populations were large, flat, and triangular or
polygonal, and some had tapering extensions (Fig. 3A). Very
few cells with neuronal morphologies were observed on the
layer of astrocytes. In the control population, cells had
small, refractive cell bodies and branched neurite exten-
sions typical of neurons (Fig. 3B).Figure 2 Gene expression in differentiating hNP cells to identify op
performed for astrocytic differentiation markers and relative expressi
diagrams show average expression of (A) CD44 and (B) S100B in cells tre
(50 nM) and BMP2 (20 ng/mL). In a separate culture, in the presence of
and (D) S100B] were quantified. Data indicate that up to 500 nMof Aza-
Here, NP and UT represent starting undifferentiated cells and neurona
relative expressions of proastrocytic genes (E) CD44, (F) S100B, (G) A
increasing concentrations of TSA against different levels of Aza-C and
(UT) neuronal cultures relative to undifferentiated cells (NP). Transcr
ANOVA followed by multiple comparisons using Tukey's test was pe
difference at p b 0.05 level.Immunocytochemistry data showed that a large fraction
of cells in treated populations were positive for GFAP
(Fig. 3C) and S100B (Fig. 3D) at d15. The GFAP immunore-
activity was weak and cytoplasmic while S100B was observed
in both nucleus and cytoplasm (Fig. 3D). Untreated cells
showed no immunoreactivity. Flow cytometry of d15
cultures indicated that the population was 20.9% ± 0.81
GFAP+ and 80.7% ± 0.83 S100B+ cells (Figs. 3C and D).
When the cultures were extended an additional 15 days
(d30) in the same conditions, S100B+, GLAST+, CD44+ as well
as ALDH1L1+ were detected by immunostaining. Most of
these cells also co-stained weakly with GFAP (Figs. 3E–G). At
both d15 and d30, GFAP and S100B negative cells were
morphologically similar to the expressing cells. Approxi-
mately 58.44% ± 6.8 cells expressed S100B, and included
strong (12% ± 3.7) as well as weakly (45.05 ± 3.04) immuno-
reactive cells. A very small fraction of cells showed very
strong GFAP expression. Additionally a fraction of cells
expressed CD44 and included both strong (9% ± 2.8) and
weakly (28.6% ± 4.1) immunoreactive cells. In ALDH1L1+ and
GFAP+ stained cells, the ALDH1L1 immunoreactivity was
punctate and usually surrounding the nucleus (Fig. 3G).
Similar ALDH1L1 staining pattern was obtained when human
fetal derived astrocytes were stained with the same
antibody (data not shown).
To further confirm the cellular identity of the cells in
culture, we compared expression levels of several neuronal
and astrocytic genes between treated and untreated
cultures at d15 and d30 (Fig. 4). The astrocytic genes
CD44, S100B, AQP4 and GJA1 were expressed at significantly
higher levels (p b 0.05) in treated cultures at both day 15
and 30 compared to corresponding untreated controls.
Although an uptrend was observed for BDNF in treated
cultures at d15, a significant (p b 0.05) increase was
observed only at d30. GFAP expression was detected at
both d15 and d30, and d30 was significantly higher than d15.
No GFAP transcripts were detected in either hNP or UT
differentiation cultures (data not shown). Expression of
SLC1A2, a glutamate transporter, was significantly higher for
both treated and untreated populations at d30 compared to
d15. The early neuronal marker NEUROD1 was detected in
untreated controls at d15, with a reduction at d30, and was
not detected in treated cultures at d30. Transcript levels of
the mature neuronal marker MAP2 were highest in untreated
cultures at d30, with significantly lower expression in the
corresponding treated cultures (p b 0.05). Together therewas
a significant increase in astrocytic gene expression and
decreased levels of neuronal gene expression in proastrocytic
cultures. Azacytidine (Aza-C) and Trichostatin A (TSA) cantimal treatments for astrocytic differentiation.Quantitative PCR is
on of these markers is presented as bar diagrams (mean ± SE). Bar
ated with combinations of FGF2 (10 ng/mL), Aza-C (1000 nM), TSA
an increasing Aza-C dosage, expressions of thesemarkers [(C) CD44
C is sufficient to differentiate hNP cells expressing CD44 and S100B.
l differentiation, respectively. Therefore, in the next experiment,
LDH1L1 and (H) GDNF were quantified for cultures treated with
a constant level of BMP2. (I) Expression of NEUROD1 in untreated
ipts were not detected in any of the remaining treatments tested.
rformed. n = 3. Different superscripts on bars imply significant
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conducted viability assays after 30 days of differentiation.
Our results indicate a viability of 81% (±3.85), which is
comparable to control neuronal cultures.
Dynamic epigenetic regulation of astrocytic genes
during proastrocytic differentiation
To investigate the potential mechanisms by which our
method regulates the expression of astrocytic genes, we
analyzed the DNA methylation status of the promoter
regions of astrocyte progenitor gene CD44 (Figs. 5A and C),
and astrocyte genes S100B and GFAP (Figs. 5B and C).
Bisulfite sequencing analysis showed that 40% of the CpG
sites at the CD44 promoter region were methylated in
cultured hNP cells with specific CpG sites being completely
methylated (Figs. 5A and C). However, DNA methylation at
the CD44 promoter was largely lost following withdrawal of
FGF2 for 5 days (Untreated, UT) (p b 0.0001), and the
promoter remained unmethylated in all treatments: BMP2
alone (BMP2) or BMP2 and Aza-C combined with TSA at two
different concentrations (BMP2, Aza-C, TSA 10 nM or BMP2,
Aza-C, TSA 20 nM) (Figs. 5A and C). In contrast to CD44, both
GFAP and S100B were completely methylated in hNP cells.
While removal of FGF2 and addition of BMP2 did not lead to
significant changes in DNA methylation in these two genes,
treatment with Aza-C and TSA caused significant increases in
the percentage of unmethylated CpGs, with a larger effect
on S100B than GFAP (Figs. 5B and C; p b 0.01 and
p ≤ 0.0001, respectively). These results demonstrate that
treatment of Aza-C and TSA leads to reduced levels of DNA
methylation at GFAP and S100B.
We next analyzed the status of two active histonemarks, H3
lysine 9 acetylation (H3K9Ac) and H3 lysine 4 trimethylation
(H3K4me3), at the promoters of CD44 and the astrocyte genes
GFAP, S100B and AQP4 by quantitative chromatin immunopre-
cipitation (qChIP). As expected, H3K9Ac showed a dosage
dependence on the concentration of TSA, an inhibitor of histone
deacetylases (Fig. 6A, BMP2, Aza-C, TSA 10 nM vs BMP2, Aza-C,
TSA 20 nM). The increases in H3K9 acetylation on proastrocytic
genes correlate with increased levels of the active histone
methylation mark, H3K4me3. H3K4me3progressively increased
with the addition of Aza-C and an increasing dose of TSA at
astrocytic progenitor gene or astrocyte genes, but not at the
house-keeping gene GAPDH (Fig. 6B). These results indicate the
specific effects on the epigenetic regulation of astrocytic genes
by concomitant treatment with Aza-C, TSA and BMP2.
Discussion
Human NP cells (hNP) differentiate readily to form neurons
upon withdrawal of FGF2 from proliferation medium. By
15 days, a majority of the cells acquire neuronal morphologies
and express a multitude of neuronal markers. However, even
after long term differentiation (up to 125 days), there is a
marked lack of astrocytic morphologies andmarker expression
(Young et al., 2011). Our study points to possible reasons for
this neurogenic bias and provides a method for shifting this
bias to produce an astrocytic population in a short period of
time. To our knowledge, this is the first report describing the
use of Aza-C and TSA to obtain astrocytes in such a short timefrom human ES derived adherent NP cells. With the described
treatments, in as little as 10–15 days, most, if not all cells in
the population exhibit astrocytic morphologies, distinctly
deviating from untreated cultures.BMP2 inhibits neuronal specification but does not
promote astrocytogenesis in human hNP cells
Synergism of BMP and LIF signaling is an established
effector for astrocytic differentiation in primary cultures
of rodent NP cells (Nakashima et al., 1999; Yanagisawa
et al., 2001; Koblar et al., 1998). In a previous report
on generation of astrocytes from human ESC, neural
aggregates were dissociated and cultured for a month to
get homogenous progenitors and another 55 days till
they expressed BMP and LIF receptors. At this time the
cells responded to BMP4 and LIF with astroglial specifi-
cation (Gupta et al., 2012). However, our results
indicate that hNP cells derived from hESC as adherent
monolayers express LIF and BMP receptors but remain
refractive to astroglial specification.
We have reported earlier that LIF signaling has a strong
neurogenic effect during postmitotic differentiation of hNP
cells (Majumder et al., 2012). Consistent with this, hNP cells
differentiatedwith LIF butwithout BMP2 show a large increase
in expression of NEUROD1 (Fig. 1A) and these cultures display a
distinctly neuronal phenotype (by morphology). NEUROD1, a
marker for early neuronal differentiation, promotes expres-
sion of Neurogenins that are known to inhibit astrocytogenesis
and drive differentiation down the neuronal lineage (Sun et
al., 2001). Further, our results here show that LIF and BMP2
signaling together, at least in the early phases of differenti-
ation (up to 2 weeks), suppress neurogenesis, as reflected by
significant reduction in NEUROD1 expression (Fig. 1A), but do
not induce astroglial differentiation. Suppression of the
preferred neurogenic pathway may, however, have a permis-
sive effect on astrocytogenesis.
In both BMP2+ and BMP2− differentiation, reduced
expression of the astrocyte progenitor marker CD44 (Liu
et al., 2004) and the astrocyte marker S100B is consistent
with previously observed lack of astrocytic potential of
these hNP cells (Young et al., 2011; Dhara et al., 2008).
These data show that hNP cells are able to respond to BMP2
and that BMP2 is inhibitory to neuronal differentiation but
not instructive in astrocytogenesis in early stages of
differentiation.
When hNP cells were differentiated for a prolonged
period (~2 months) in the presence of BMP2, a small
fraction of cells expressed S100B and GFAP (Fig. 1D). It has
been previously reported that, in neural progenitors
cultured and expanded as aggregates, a small fraction of
cells spontaneously express S100B at 30 days and GFAP
expressing cells begin to appear at about 2 months (Krencik
et al., 2011). This, however, is without addition of extrinsic
BMP2. In contrast, the adherent hNP cells differentiated
without BMP2 do not spontaneously differentiate to
astroglial phenotypes when cultured up to 4 months
(Young et al., 2011). Our results suggest that at least some
cells in the differentiating population do acquire a
proastrocytic BMP2 response with time. The fact that hNP
cells are primarily neurogenic and do not respond to BMP2
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Figure 3 Morphology and gene expression after 15 and 30 days of differentiation of cells with astrocytic treatment. Bright field
images of hNP cells differentiated (A) with or (B) without astrocytic treatment. A and B compare morphology of cultured cells in
treated vs. untreated differentiation at 15 days. Treated and untreated cells were cryopreserved at d6 and subsequently thawed and
cultured for an additional 9 days. Flow cytometry analysis to determine percent of GFAP+ and S100B+ cells at d15 of differentiation.
Data is presented as histograms for (C) GFAP and (D) S100B with corresponding immunoreactive cells in insets from a parallel culture.
Immunocytochemistry detects expression of (E) GFAP with S100B (inset showing distinct staining for both markers), (F) GFAP with
GLAST, and (G) GFAP with ALDH1L1 at d30 of differentiation.
581Astrocyte differentiation from human embryonic stem cellsand LIF signaling to produce astrocytes is reflective of
rodent NP cells isolated from the early embryonic brain.
These NP cells are not responsive to BMP2 and LIF until
mid-gestation when they acquire astrocytic potential
(Temple, 2001; Molne et al., 2000), and thus possibly
represent early in vivo neuroepithilia.
Since BMP2 and LIF failed to generate astrocytes from
hNP cells we examined the role of epigenetic regulation for
glial differentiation. Changes in DNA methylation are
critical for the switch from early neurogenic to late
gliogenic potential of progenitor cells in the developing
rodent brain (Fan et al., 2005; Wu et al., 2003; Shimozaki etal., 2005). The inability of early rodent embryonic brain
cells to produce astrocytes is attributed to promoter
hypermethylation of prominent astrocytic genes (Takizawa
et al., 2001), and the developmental shift in response is
attributed to demethylation of these gene promoters during
later stages of development (Hatada et al., 2008). The
hypermethylation of GFAP, S100B and AQP4 that we
detected in hNP cells, is correlative with the phenomenon
described in the early mouse embryonic brain. Even after
prolonged culture and passaging, the hNP cells remain
proneuronal, with hypermethylated states maintained.
Although not tested, we speculate that this is due to a lack
Figure 4 Astrocytic and neuronal gene expression analysis at 15 and 30 days of astrocytic and neuronal differentiation. Quantitative
PCR was performed to detect both astrocytic and neuronal markers in hNP cells differentiated for 15 and 30 days. The mean (±SE) of
replicates (n = 3) is presented as bar diagrams. ANOVA followed by Tukey's test for multiple comparisons was conducted. Panel (A)
shows expression of astrocytic genes (CD44, S100B, AQP4, BDNF, GJ1, and SLC1A2) calibrated to undifferentiated hNP cells. All genes
expressed significantly higher in amount at both day 15 and 30 of differentiation compared to untreated control. GJ1 had higher
relative expression at day 15 whereas remaining genes had the highest expression at day 30 of differentiation. Panel (B) shows
neuronal gene (NEUROD1 and MAP2) expression of untreated and treated populations. Differentiation promoted expression of
neuronal markers in the untreated group which were significantly higher than the treated group. n = 3. Bars represent mean relative
quantities within each gene and different superscripts within each gene imply significant differences (p b 0.05).
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ment of an embryoid body or in a developing embryo.Combined exposure to Aza-C and TSA leads to early
astrocytic differentiation
Azacytidine (Aza-C) is a DNA methyltransferase inhibitor that
causes DNA demethylation (Juttermann et al., 1994; Santi et
al., 1984). The demethylation of astroglial gene promoters
enhances the competence of rodent neural progenitors to
respond to astrogliogenic signals and cytokines such as BMP2,
CNTF and LIF, enabling astrocytosis (Takizawa et al., 2001).
Histone acetylation is another critical epigenetic controlling
mechanism for neurogenesis (Mattson, 2003; Asano et al., 2009;
Sanosaka et al., 2008) and has been implicated in astrocyte
specification in the rodent (Freeman, 2010). Trichostatin-A
(TSA) is a class I and II mammalian histone deacetylase (HDAC)
inhibitor and can alter gene expression by interfering with the
removal of acetyl groups from histones. The effects of TSA,
however, depend to some extent on the target progenitor cells.
In rodent embryonic neural stem cells undergoing in vitro
differentiation, TSA promotes neuronal differentiation and
appears to inhibit astrocytogenesis (Balasubramaniyan et al.,
2006). However, the neural progenitor cells extracted from the
adult hippocampal region of mouse differentiated into astro-
cytes upon HDAC inhibition, and addition of LIF and BMP (Gage
et al., 1995; Chireux et al., 1996; Hersh and Shimojo, 2003).
Given these progenitor-specific differences, it is necessary to
specifically test its role in the context of the cell type of
interest, that is, hES derived hNP cells.Here we found that concomitant BMP2 and Aza-C treat-
ment was needed for astrocytic differentiation of hNP cells
(Figs. 2A and B). We showed that expression of both CD44 and
S100B increases in a dose dependent manner for Aza-C, in a
background of constant BMP2 and LIF, suggesting that Aza-C
promoted both astrocytic progenitor fates (CD44) and matu-
ration (S100B) (Figs. 2C and D). However, increasing the
amounts of TSA in a background of constant Aza-C and BMP2
shows TSA dose dependence for expression of S100B (Fig. 2F),
but not for CD44 (Fig. 2E), suggesting that TSAmay be relevant
to generation of the more mature phenotypes. ALDH1L1,
which is expressed in rodent brain derived astrocytes (Anthony
and Heintz, 2007; Fu et al., 2009), is expressed in treated hNP
cells. ALDH1L1 expression depended more on Aza-C concen-
tration than on TSA concentration (Fig. 2G). GDNF, another
established marker of astrocytes, was expressed only in
treated cells and not in the untreated cells (Fig. 2H), a further
indication that these were proastrocytic treatments.
Multiple morphologies, including large flat triangular and
polygonal cells, often with long tapering extensions and some
with vacuolar structures seen in the treated hNP cell cultures
(Figs. 3A and B), are similar to those described in detail for
mouse astrocytes cultured in vitro (Matyash and Kettenmann,
2010). Astrocytic identity at this time is also confirmed by
S100B and GFAP immunocytochemistry (Figs. 3C and D). During
astroglial specification from hES derived neurospheres, S100B
expression is observed in about 8% of cells at day 30 and GFAP
expressing cells start to appear at about day 60, with changes
in morphology in a corresponding fraction of cells (Krencik et
al., 2011). In contrast, we observed S100B expression in a
majority of cells within 15 days (Fig. 3F) along with GFAP
Figure 5 Changes in DNA methylation at astrocytic promoters following Aza-C and TSA treatment. Bisulfite sequencing analysis of
DNA methylation status at promoters of (A) astrocyte progenitor gene CD44, and (B) the astrocyte genes S100B and GFAP. The position
of CpG sites analyzed is indicated as vertical ticks on the line. TSS: transcription start site. Open circles: unmethylated CpG sites;
closed circles: methylated CpG sites. (C) Percentage of unmethylated CpG sites. n = 3. Statistical analysis was performed using
Fisher's exact test.*: p b 0.05, **: p b 0.01, ****: p ≤ 0.0001.
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morphology throughout the treated cultures, and complete
morphological divergence between the treated and untreated
hNP populations further demonstrates the effectiveness of the
treatment. After further differentiation/maintenance, at day
30, we still detect expression of both S100B and GFAP, and a
major fraction of cells co-express both. The expression levels
of S100B fall within a wide range. GFAP remains low in
majority of the cells compared to fetal brain cell control and
possibly indicate non-reactive astrocytes that do not often
express GFAP at an immunohistochemically detectable level
(Sofroniew and Vinters, 2010). The small and scattered
clusters of strong GFAP positive cells are likely spontaneously
reactivated astrocytes. ALDH1L1 and GLAST immunoreactivity
further confirmed the astrocytic identity at this stage (Fig. 3).
Additionally the presence of a CD44 immunoreactive fractionsuggests that astrocytic progenitors are still present at this
stage.Aza-C andTSA treatment promotes specific epigenetic
changes at proastrocytic gene promoters
Removal of FGF2 resulted in a significant demethylation at
the CD44 promoter region even in the absence of Aza-C
treatment. This suggests that FGF2 was required for
maintenance of DNA methylation and repression of CD44
expression. It is interesting to note that treatment with
Aza-C and TSA caused nearly complete depletion of
methylated CpG in the CD44 promoter in the population,
suggesting that Aza-C and TSA treatment prevents DNA
methylation and stabilizes an active state of CD44 promoter.
Figure 7 Schematic diagram explaining possible events of
astrocyte differentiation with human neural progenitors. Human
neural progenitors (hNP) are generated from human ES cells as per
described protocol. Presence of FGF2 in culture prevents differen-
tiation of hNP cells into terminal fates such as neurons and glia
(astrocytes and oligodendrocytes) and maintains proliferative
state, allowing expansion. Withdrawal of FGF2 triggers differenti-
ation and in the absence of any instructive signal, mostly pure
neuronal cultures are obtained. BMP2 signaling, which is known to
prevent neuronal differentiation, drastically reduces expression of
neuronal markers in the differentiated culture. However, BMP2
alone is not sufficient to drive differentiation along the astrocyte
lineage. Promoters of pro-astrocytic genes are found to be
methylated in hNP cells. Therefore, to overcome this epigenetic
blockage, methylation inhibitor Aza-C, in the presence of TSA and
another instructive signal, LIF, is used and the cultures become
primarily of astrocytic in nature.
Figure 6 Quantitative chromatin immunoprecipitation (qChIP) analysis of histone marks at astrocytic promoters following Aza-C
and TSA treatment. The levels of (A) H3K9Ac and (B) H3K4me3 were analyzed by qChIP and normalized to input controls. Fold
enrichment was represented as fold changes over that of histone H3. The dashed line indicates the highest signal level of control IgG
qChIP. n = 3. Data are presented as mean ± SD. *: p b 0.05, **: p b 0.01, ***: p b 0.001.
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repressed in hNP cells without any significant reduction in
methylation by removal of FGF2 or by addition of BMP2 in
culture. Here, we show that a higher dose of TSA leads to an
increased level of H3K9Ac acetylation, supporting a role for
TSA in inhibiting histone deacetylation. Additionally, the
levels of the active mark H3K4me3 also increase at astrocyte
genes, further suggesting an active state of these promoters.
Interestingly, the impact of Aza-C and TSA on the epigenetic
profiles of these astrocyte genes appears to be specific.
These results suggest that Aza-C and TSA promote the
transition of the promoters of these astrocytic genes from an
inactive to active state, facilitating the rapid up-regulation
of the gene expression under the in vitro conditions we
developed here using small molecules.
Given our data, it is likely that overall astrocytic
differentiation is governed by FGF2, BMP2 and LIF signaling
in hNP cells pre-exposed to Aza-C and TSA (Fig. 7). FGF2, a
mitogen, maintains undifferentiated progenitor cell state
negatively regulating hNP cell differentiation. Once FGF2 is
withdrawn, hNP cells readily become postmitotic neuronal
cells. However, even in the presence of instructive signals
such as BMP2 and LIF, they did not differentiate towards
astrocytes. BMP2, along with STAT3 activated by LIF,
prevents NEUROGENIN expression and subsequently expres-
sion of NEUROD1, inhibiting neuronal differentiation. When
hNP cells are pre-exposed to the DNMT inhibitor Aza-C, hNP
cells become competent for astrocytogenesis upon addition-
al exposure to BMP2 and LIF signaling. This suggests that hES
derived hNP cells represent early embryonic neuroepithelial
cells in terms of glial potential and epigenetics. The removal
of hypermethylation gives a quick and defined way to
produce highly enriched astrocytes from hNP cells in a very
short time.
Alternatively, Aza-C and TSA may have multiple effects on
the hNP cells beyond effecting epigenetic marks on the
proastrocytic genes probed. The ability to produce a highly
enriched and cryopreservable population of either astrocytes
or neurons from the same source will make it possible to
co-culture astrocytes and neurons in defined ratios, making itpossible to design controlled experiments and assays. Also,
this approach eliminates serum commonly used to generate
astrocytes increasing the scope of applications for these cells.
585Astrocyte differentiation from human embryonic stem cellsFurther, this process will allow comparative studies due to
early divergence of the two populations and the short time
required for appearance of fate specific markers.
Acknowledgments
This material is based upon thework supported by theNational Science
Foundation under the Science and Technology Center Emergent
Behaviors of Integrated Cellular Systems (EBICS) Grant No. CBET-
0939511 to SLS and YF, and a Georgia Cancer Coalition Distinguished
Scholar Award to YF. Authors would like to thank Ms. Julie Nelson of
the Center for Tropical and Emerging Global Diseases Flow Cytometry
Facility for her technical expertise and Ms. Erin Jordan for technical
support.
References
Anthony, T.E., Heintz, N., 2007. The folatemetabolic enzyme ALDH1L1
is restricted to the midline of the early CNS, suggesting a role in
human neural tube defects. J. Comp. Neurol. 500, 368–383.
Asano, H., Aonuma, M., Sanosaka, T., et al., 2009. Astrocyte
differentiation of neural precursor cells is enhanced by retinoic
acid through a change in epigenetic modification. Stem Cells 27,
2744–2752.
Balasubramaniyan, V., Boddeke, E., Bakels, R., et al., 2006. Effects
of histone deacetylation inhibition on neuronal differentiation of
embryonic mouse neural stem cells. Neuroscience 143, 939–951.
Bock, C., Reither, S., Mikeska, T., et al., 2005. BiQ Analyzer:
visualization and quality control for DNA methylation data from
bisulfite sequencing. Bioinformatics 21, 4067–4068.
Cahoy, J.D., Emery, B., Kaushal, A., et al., 2008. A transcriptome
database for astrocytes, neurons, and oligodendrocytes: a new
resource for understanding brain development and function.
J. Neurosci. 28, 264–278.
Chen, G., Hou, Z., Gulbranson, D.R., et al., 2010. Actin–myosin
contractility is responsible for the reduced viability of dissoci-
ated human embryonic stem cells. Cell Stem Cell 7, 240–248.
Chireux, M., Espinos, E., Bloch, S., et al., 1996. Histone
hyperacetylating agents stimulate promoter activity of human
choline acetyltransferase gene in transfection experiment. Brain
Res. Mol. Brain Res. 39, 68–78.
Dhara, S.K., Hasneen, K., Machacek, D.W., et al., 2008. Human
neural progenitor cells derived from embryonic stem cells in
feeder-free cultures. Differentiation 76, 454–464.
Fan, G., Martinowich, K., Chin, M.H., et al., 2005. DNA methylation
controls the timing of astrogliogenesis through regulation of
JAK–STAT signaling. Development 132, 3345–3356.
Fatemi, S.H., Folsom, T.D., Reutiman, T.J., et al., 2008. Expression
of astrocytic markers aquaporin 4 and connexin 43 is altered in
brains of subjects with autism. Synapse 62, 501–507.
Freeman, M.R., 2010. Specification and morphogenesis of astro-
cytes. Science 330, 774–778.
Fu, H., Cai, J., Clevers, H., et al., 2009. A genome-wide screen for
spatially restricted expression patterns identifies transcription
factors that regulate glial development. J. Neurosci. 29,
11399–11408.
Gage, F.H., Coates, P.W., Palmer, T.D., et al., 1995. Survival and
differentiation of adult neuronal progenitor cells transplanted to
the adult brain. Proc. Natl. Acad. Sci. U. S. A. 92, 11879–11883.
Gonzalez-Gomez, P., Bello, M.J., Arjona, D., et al., 2003. Promoter
hypermethylation of multiple genes in astrocytic gliomas. Int. J.
Oncol. 22, 601–608.
Gupta, K., Patani, R., Baxter, P., et al., 2012. Human embryonic
stem cell derived astrocytes mediate non-cell-autonomous
neuroprotection through endogenous and drug-induced mecha-
nisms. Cell Death Differ. 19, 779–787.Hatada, I., Namihira, M., Morita, S., et al., 2008. Astrocyte-specific
genes are generally demethylated in neural precursor cells prior
to astrocytic differentiation. PLoS One 3, e3189.
Hersh, L.B., Shimojo, M., 2003. Regulation of cholinergic gene
expression by the neuron restrictive silencer factor/repressor
element-1 silencing transcription factor. Life Sci. 72,
2021–2028.
Juttermann, R., Li, E., Jaenisch, R., 1994. Toxicity of 5-aza-2′-
deoxycytidine to mammalian cells is mediated primarily
by covalent trapping of DNA methyltransferase rather than
DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 91,
11797–11801.
Koblar, S.A., Turnley, A.M., Classon, B.J., et al., 1998. Neural
precursor differentiation into astrocytes requires signaling
through the leukemia inhibitory factor receptor. Proc. Natl.
Acad. Sci. U. S. A. 95, 3178–3181.
Krencik, R., Weick, J.P., Liu, Y., et al., 2011. Specification of
transplantable astroglial subtypes from human pluripotent stem
cells. Nat. Biotechnol. 29, 528–534.
Liu, Y., Han, S.S., Wu, Y., et al., 2004. CD44 expression identifies
astrocyte-restricted precursor cells. Dev. Biol. 276, 31–46.
Majumder, A., Banerjee, S., Harrill, J.A., et al., 2012.
Neurotrophic effects of leukemia inhibitory factor on neural
cells derived from human embryonic stem cells. Stem Cells 30,
2387–2399.
Mattson, M.P., 2003. Methylation and acetylation in nervous system
development and neurodegenerative disorders. Ageing Res. Rev.
2, 329–342.
Matyash, V., Kettenmann, H., 2010. Heterogeneity in astrocyte
morphology and physiology. Brain Res. Rev. 63, 2–10.
Molne, M., Studer, L., Tabar, V., et al., 2000. Early cortical
precursors do not undergo LIF-mediated astrocytic differentia-
tion. J. Neurosci. Res. 59, 301–311.
Nakashima, K., Yanagisawa, M., Arakawa, H., et al., 1999. Astrocyte
differentiation mediated by LIF in cooperation with BMP2. FEBS
Lett. 457, 43–46.
Ohgushi, M., Matsumura, M., Eiraku, M., et al., 2010. Molecular
pathway and cell state responsible for dissociation-induced
apoptosis in human pluripotent stem cells. Cell Stem Cell 7,
225–239.
Sanosaka, T., Namihira, M., Asano, H., et al., 2008. Identification of
genes that restrict astrocyte differentiation of midgestational
neural precursor cells. Neuroscience 155, 780–788.
Santi, D.V., Norment, A., Garrett, C.E., 1984. Covalent bond
formation between a DNA-cytosine methyltransferase and DNA
containing 5-azacytosine. Proc. Natl. Acad. Sci. U. S. A. 81,
6993–6997.
Shimozaki, K., Namihira, M., Nakashima, K., et al., 2005. Stage-
and site-specific DNA demethylation during neural cell
development from embryonic stem cells. J. Neurochem. 93,
432–439.
Shin, S., Mitalipova, M., Noggle, S., et al., 2006. Long-term
proliferation of human embryonic stem cell-derived neuroepithelial
cells using defined adherent culture conditions. Stem Cells 24,
125–138.
Sofroniew, M.V., Vinters, H.V., 2010. Astrocytes: biology and
pathology. Acta Neuropathol. 119, 7–35.
Sun, Y., Nadal-Vicens, M., Misono, S., et al., 2001. Neurogenin
promotes neurogenesis and inhibits glial differentiation by
independent mechanisms. Cell 104, 365–376.
Takizawa, T., Nakashima, K., Namihira, M., et al., 2001. DNA
methylation is a critical cell-intrinsic determinant of astrocyte
differentiation in the fetal brain. Dev. Cell 1, 749–758.
Temple, S., 2001. The development of neural stem cells. Nature
414, 112–117.
Wu, Y., Liu, Y., Levine, E.M., et al., 2003. Hes1 but not Hes5
regulates an astrocyte versus oligodendrocyte fate choice in glial
restricted precursors. Dev. Dyn. 226, 675–689.
586 A. Majumder et al.Wu, S.X., Goebbels, S., Nakamura, K., et al., 2005. Pyramidal
neurons of upper cortical layers generated by NEX-positive
progenitor cells in the subventricular zone. Proc. Natl. Acad. Sci.
U. S. A. 102, 17172–17177.
Yan, H., Parsons, D.W., Jin, G., et al., 2009. IDH1 and IDH2
mutations in gliomas. N. Engl. J. Med. 360, 765–773.
Yanagisawa, M., Nakashima, K., Takizawa, T., et al., 2001. Signaling
crosstalk underlying synergistic induction of astrocyte differentia-
tion by BMPs and IL-6 family of cytokines. FEBS Lett. 489, 139–143.Young, A., Machacek, D.W., Dhara, S.K., et al., 2011. Ion channels
and ionotropic receptors in human embryonic stem cell derived
neural progenitors. Neuroscience 192, 793–805.
Yuan, S.H., Martin, J., Elia, J., et al., 2011. Cell-surface marker
signatures for the isolation of neural stem cells, glia and neurons
derived from human pluripotent stem cells. PLoS One 6, e17540.
Zhang, Y., Cooke, M., Panjwani, S., et al., 2012. Histone h1
depletion impairs embryonic stem cell differentiation. PLoS
Genet. 8, e1002691.
